http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105560219-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2014-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105560219-B |
| titleOfInvention | Use of fingolimod or a salt thereof in the treatment of cystic disease |
| abstract | The invention provides application of Fingolimod (2-amino-2- [2- (4-octylphenyl) ethyl ] -1, 3-propanediol or Fingolimod) or a salt thereof in preparing a pharmaceutical composition for treating cystic diseases. Specifically, the inventors found that Fingolimod (Fingolimod) or a salt thereof has an effect of inducing apoptosis and/or inhibiting proliferation of cyst cells by inhibiting HDACs and blocking the cell cycle of the cyst cells in the G2/M phase, thereby reducing cyst volume and restoring renal function. In addition, cytotoxicity experiments also confirmed that fingolimod at therapeutic doses, known as the drug on the market, also had no apparent toxicity when used to treat cystic disease. Fingolimod has wide application prospect as a medicament for treating cystic diseases, particularly autosomal dominant polycystic kidney disease. |
| priorityDate | 2014-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 75.